Table 3.
Absolute measures | Mepolizumab vs. placebo [95% CI] |
Reslizumab vs. placebo [95% CI] |
Mepolizumab vs. reslizumab [95% CI] | |
---|---|---|---|---|
Lung function FEV1 | Mean difference | 99.11 [52.80; 145.41] | 125.63 [76.73; 174.54] | −26.52 [−93.87; 40.83] |
Asthma control questionnaire ACQ | Mean difference | −0.34 [−0.50; −0.19] | −0.26 [−0.34; −0.18] | −0.08 [−0.25; 0.09] |
Quality of life (AQLQ and SGRQ) | SMD | 0.33 [0.11; 0.55] | 0.30 [0.18; 0.42] | 0.03 [−0.22; 0.28] |